Gilead, Vir partner for HBV combination research

Gilead Sciences and Vir Biotechnology will collaborate on a study to research novel combination therapies for patients with chronic hepatitis B virus, according to a Gilead press release.The two companies will work together on a phase 2 trial aimed at finding a functional cure for HBV using different combinations of treatments they manufacture, selgantolimod and VIR-2218.“Gilead has a 2-decade commitment to people with hepatitis B and we have worked tirelessly to bring new treatments forward with the goal of helping to improve their lives,” Anuj Gaggar, vice president of clinicalRead More

Share on facebook
Share on twitter
Share on linkedin